Drug
Mivavotinib clinical trials
Also written TAK-659.
Includes 10 studies of TAK-659.
- studies test it
- 13
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2019 (4)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 4 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 3
Calithera Biosciences, Inc (10) · Northwestern University (1) · M.D. Anderson Cancer Center (1) · H Scott Boswell (1)
Often tested with
Tested in the same studies.
Paclitaxel (1) · Venetoclax (1) · Ixazomib (1) · Nivolumab (1) · Bempegaldesleukin (1)
Studies
Open first, then newest update. How each study uses mivavotinib is read from its arms, and is right about nine times in ten.
Testing it · 13
- Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell LymphomaCompletedPhase 1Northwestern UniversityNCT03742258Written as Spleen Tyrosine Kinase Inhibitor TAK-659
- Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor IxazomibTerminatedPhase 1/2H Scott BoswellNCT04079738Written as TAK-659
- Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedPhase 2Calithera Biosciences, IncNCT05319028Written as Mivavotinib
- TAK-659 and Paclitaxel in Treating Patients With Advanced Solid TumorsCompletedPhase 1M.D. Anderson Cancer CenterNCT03756818Written as Mivavotinib
- A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin LymphomaCompletedPhase 1Calithera Biosciences, IncNCT03357627Written as TAK-659
- A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma MalignanciesCompletedPhase 1Calithera Biosciences, IncNCT02000934Written as TAK-659
- Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)TerminatedPhase 1/2Calithera Biosciences, IncNCT02323113Written as TAK-659
- A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)TerminatedPhase 1Calithera Biosciences, IncNCT03238651Written as TAK-659
- TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedPhase 2Calithera Biosciences, IncNCT03123393Written as TAK-659
- A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid TumorsTerminatedPhase 1Calithera Biosciences, IncNCT02834247Written as TAK-659
- A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma MalignanciesWithdrawnPhase 1Calithera Biosciences, IncNCT03338881Written as [14C]-TAK-659
- A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)WithdrawnPhase 1Calithera Biosciences, IncNCT03772288Written as TAK-659
- A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid TumorWithdrawnPhase 1Calithera Biosciences, IncNCT03359733Written as TAK-659
Given in every arm · 2 — mivavotinib is usual care beside what is tested
- A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin LymphomaTerminatedPhase 1Millennium Pharmaceuticals, Inc.NCT02954406Written as TAK-659
- MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal AdenocarcinomaTerminatedPhase 1Millennium Pharmaceuticals, Inc.NCT02551055Written as TAK-659
Codes
What other systems call mivavotinib · ClinicalTrials.gg INT015704
- UNII (FDA) 8QR88H79VXMIVAVOTINIBConfirmed FDA, Wikidata
- Wikidata Q105337798mivavotinibConfirmed FDA, Wikidata
- NCI Thesaurus C113162MivavotinibOne source FDA
- DrugBank DB16849One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 8QR88H79VX | MIVAVOTINIB | Confirmed FDA, Wikidata |
| Wikidata | Q105337798 | mivavotinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C113162 | Mivavotinib | One source FDA |
| DrugBank | DB16849 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.